-
1
-
-
78650589643
-
What is value in health care?
-
Porter M. What is value in health care?. NEJM 2010, 363(26):2477-2481.
-
(2010)
NEJM
, vol.363
, Issue.26
, pp. 2477-2481
-
-
Porter, M.1
-
3
-
-
84878544006
-
The impact of the profile of biologics on treatment costs
-
Leardini G., Rigon C. The impact of the profile of biologics on treatment costs. Autoimmun Rev 2013, 12(8):842-847.
-
(2013)
Autoimmun Rev
, vol.12
, Issue.8
, pp. 842-847
-
-
Leardini, G.1
Rigon, C.2
-
4
-
-
84878622273
-
Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?
-
Modena V., Bianchi G., Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?. Autoimmun Rev 2013, 12(8):835-838.
-
(2013)
Autoimmun Rev
, vol.12
, Issue.8
, pp. 835-838
-
-
Modena, V.1
Bianchi, G.2
Roccatello, D.3
-
5
-
-
84866846273
-
Biologic drugs in autoinflammatory syndromes
-
[Review]
-
Caorsi R., Federici S., Gattorno M. Biologic drugs in autoinflammatory syndromes. Autoimmun Rev 2012, 12(1):81-86. [Review].
-
(2012)
Autoimmun Rev
, vol.12
, Issue.1
, pp. 81-86
-
-
Caorsi, R.1
Federici, S.2
Gattorno, M.3
-
6
-
-
84874140621
-
Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development
-
Xiao Yann C., Wake A., Gouty D. Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development. Bioanalysis 2013, 5(5):517-520.
-
(2013)
Bioanalysis
, vol.5
, Issue.5
, pp. 517-520
-
-
Xiao Yann, C.1
Wake, A.2
Gouty, D.3
-
7
-
-
84886946831
-
Optimizing anti-TNF treatments in inflammatory bowel disease
-
Ben-Horin S., Kopylov U., Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014, 13(1):24-30.
-
(2014)
Autoimmun Rev
, vol.13
, Issue.1
, pp. 24-30
-
-
Ben-Horin, S.1
Kopylov, U.2
Chowers, Y.3
-
8
-
-
84871492817
-
Biosimilars: what clinicians should know
-
Narayanan S., Kruse N.A., Reichmann G., Thorpe R., Giezen C., Gravanis I., et al. Biosimilars: what clinicians should know. Blood 2012, 120:5111-5117.
-
(2012)
Blood
, vol.120
, pp. 5111-5117
-
-
Narayanan, S.1
Kruse, N.A.2
Reichmann, G.3
Thorpe, R.4
Giezen, C.5
Gravanis, I.6
-
9
-
-
70449686823
-
Avorn 1 J.Balancing innovation, access, and profits - market exclusivity for biologics
-
Engelberg A.B., Kesselheim A.S., Avorn 1 J. Balancing innovation, access, and profits - market exclusivity for biologics. N Engl J Med 2009, 361:1917-1919.
-
(2009)
N Engl J Med
, vol.361
, pp. 1917-1919
-
-
Engelberg, A.B.1
Kesselheim, A.S.2
-
10
-
-
84878558504
-
Novel diagnostic approaches and cost-benefit balance of treatment of immune-mediated and rare disease in the era of biologic drugs: lessons from the 15th Turin Congress on Immune Pathology and Orphan Disease
-
Roccatello D. Novel diagnostic approaches and cost-benefit balance of treatment of immune-mediated and rare disease in the era of biologic drugs: lessons from the 15th Turin Congress on Immune Pathology and Orphan Disease. Autoimmun Rev 2013, 12(8):793-795.
-
(2013)
Autoimmun Rev
, vol.12
, Issue.8
, pp. 793-795
-
-
Roccatello, D.1
-
11
-
-
33749345017
-
The market for follow-on biologics: how will it evolve?
-
Grabowski H., Cockburn I., Long G. The market for follow-on biologics: how will it evolve?. Health Aff (Millwood) 2006, 25:1291-1301.
-
(2006)
Health Aff (Millwood)
, vol.25
, pp. 1291-1301
-
-
Grabowski, H.1
Cockburn, I.2
Long, G.3
-
12
-
-
58349096713
-
Development and testing of a decision board to help clinicians present treatment options to lupus nephritis patients in Brazil
-
Abreu M.M., Gafni A., Ferraz M.B. Development and testing of a decision board to help clinicians present treatment options to lupus nephritis patients in Brazil. Arthritis Rheum 2009, 61:37-45.
-
(2009)
Arthritis Rheum
, vol.61
, pp. 37-45
-
-
Abreu, M.M.1
Gafni, A.2
Ferraz, M.B.3
-
13
-
-
84896544207
-
The cost of capital for early-stage biotechnology ventures
-
Harvard Business School Press, Cambridge, MA, G. Pisano (Ed.)
-
Cockburn I., Lerner J. The cost of capital for early-stage biotechnology ventures. Science business: the promise, the reality and the future of biotech 2006, 115. Harvard Business School Press, Cambridge, MA. G. Pisano (Ed.).
-
(2006)
Science business: the promise, the reality and the future of biotech
, pp. 115
-
-
Cockburn, I.1
Lerner, J.2
-
14
-
-
33748346673
-
The knowledge-value chain: a conceptual framework for knowledge translation in health
-
Landry R., Amara N., Pablos-Mendes A., Shademani R., Gold I. The knowledge-value chain: a conceptual framework for knowledge translation in health. Bull World Health Organ 2006, 84:597-602.
-
(2006)
Bull World Health Organ
, vol.84
, pp. 597-602
-
-
Landry, R.1
Amara, N.2
Pablos-Mendes, A.3
Shademani, R.4
Gold, I.5
-
15
-
-
84896544386
-
-
[accessed 8/27/13]
-
[accessed 8/27/13]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144124.pdf.
-
-
-
-
16
-
-
79952488808
-
Quality of original and biosimilar epoetin products
-
Brinks V., Hawe A., Basmeleh A.H., Joachin-Rodriguez L., Haselberg R., Somsen G.W., et al. Quality of original and biosimilar epoetin products. Pharm Res 2011, 28(2):386-393.
-
(2011)
Pharm Res
, vol.28
, Issue.2
, pp. 386-393
-
-
Brinks, V.1
Hawe, A.2
Basmeleh, A.H.3
Joachin-Rodriguez, L.4
Haselberg, R.5
Somsen, G.W.6
-
17
-
-
84873679430
-
Biosimilars in rheumatology: the wind of change
-
Schneider C.K. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis March 2013, 72(3):315-318.
-
(2013)
Ann Rheum Dis
, vol.72
, Issue.3
, pp. 315-318
-
-
Schneider, C.K.1
-
18
-
-
55349105870
-
Typical pitfalls in applications for marketing authorization of biotechnological products in Europe
-
Schneider C.K., Schäffner-Dallmann G. Typical pitfalls in applications for marketing authorization of biotechnological products in Europe. Nat Rev Drug Discov 2008, 7:893-899.
-
(2008)
Nat Rev Drug Discov
, vol.7
, pp. 893-899
-
-
Schneider, C.K.1
Schäffner-Dallmann, G.2
-
19
-
-
84873635799
-
The role of biosimilars in the treatment of rheumatic diseases
-
Dörner T., Strand V., Castañeda-Hernández G., Ferraccioli G., Isaacs G.I., Kvien T.K., et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013, 72:322-328.
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 322-328
-
-
Dörner, T.1
Strand, V.2
Castañeda-Hernández, G.3
Ferraccioli, G.4
Isaacs, G.I.5
Kvien, T.K.6
-
21
-
-
84863435547
-
The advent of biosimilar therapies in rheumatology-"o brave new world"
-
Scheinberg M.A., Kay J. The advent of biosimilar therapies in rheumatology-"o brave new world". Nat Rev Rheumatol 2012, 8:430-436.
-
(2012)
Nat Rev Rheumatol
, vol.8
, pp. 430-436
-
-
Scheinberg, M.A.1
Kay, J.2
-
22
-
-
84987994885
-
-
Institute of Medicine National Academies Press, Washington, DC
-
Institute of Medicine Performance measurement: accelerating improvement 2006, National Academies Press, Washington, DC.
-
(2006)
Performance measurement: accelerating improvement
-
-
-
24
-
-
84870242760
-
Biologic registries in rheumatology: lessons learned and expectations for the future
-
[Review]
-
Elkayam O., Pavelka K. Biologic registries in rheumatology: lessons learned and expectations for the future. Autoimmun Rev 2012, 12(2):329-336. [Review].
-
(2012)
Autoimmun Rev
, vol.12
, Issue.2
, pp. 329-336
-
-
Elkayam, O.1
Pavelka, K.2
-
25
-
-
45949108207
-
WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19-20 April 2007
-
Joung J., Robertson J.S., Griffiths E., Knezevic I. WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19-20 April 2007. Biologicals 2008, 36(4):269-276.
-
(2008)
Biologicals
, vol.36
, Issue.4
, pp. 269-276
-
-
Joung, J.1
Robertson, J.S.2
Griffiths, E.3
Knezevic, I.4
-
29
-
-
84896543744
-
-
[Accessed 12/10/13]
-
[Accessed 12/10/13]. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144941.pdf.
-
-
-
-
30
-
-
84896548506
-
-
[Accessed 8/27/13]
-
[Accessed 8/27/13]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.
-
-
-
-
31
-
-
84896543050
-
Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases
-
Desanvicente-Celis Z., Caro-Moreno J., Enciso-Zuluaga M., Anaya J.M. Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases. Biosimilars 2013, 3:1-17.
-
(2013)
Biosimilars
, vol.3
, pp. 1-17
-
-
Desanvicente-Celis, Z.1
Caro-Moreno, J.2
Enciso-Zuluaga, M.3
Anaya, J.M.4
-
32
-
-
84896549321
-
-
Available from, [Accessed October 26, 2013. Portuguese]
-
o 55 Available from, [Accessed October 26, 2013. Portuguese]. http://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2010/anexo/anexo_res0055_16_12_2010.pdf.
-
o 55
-
-
-
33
-
-
84873864303
-
Consideraciones Regulatorias sobre Productos Biológicos em Brasil
-
Araujo D.V. Consideraciones Regulatorias sobre Productos Biológicos em Brasil. Value Health Reg Issues 2012, 1:254-256.
-
(2012)
Value Health Reg Issues
, vol.1
, pp. 254-256
-
-
Araujo, D.V.1
|